ABUS
Arbutus Biopharma Corp
$4.25
+0.24%
$837.6M
No data for this timeframe.
Vol
Market Cap$837.6M
Cap SizeSmall Cap
Inst. Holders6 funds
Inst. Value$190.7M
Inst. Activity3 buys / 0 sells
Reddit Sentiment55° Neutral
SEC Reports3
Press Releases1
Recent Activity
May 13, 2026
SEC
Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.5M loss in Q1 2025,
8-K — Impact 7/10
May 13, 2026
SEC
Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in licen
PRESS-RELEASE — Impact 8/10
May 13, 2026
earnings
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><strong>Q1 total revenue of $179.1M includes estimated license revenue from Geneva
Apr 15, 2026
SEC
Arbutus Biopharma announced that the FDA has granted Fast Track designation for its investigational therapy imdusiran fo
8-K — Impact 7/10
Feb 2, 2026
Insider
Nguyen Tuan sold 73,500 shares
Chief Financial Officer @ $0.00 ($0.00)
Feb 2, 2026
Insider
Nguyen Tuan sold 188,400 shares
Chief Financial Officer @ $0.00 ($0.00)
Feb 2, 2026
Insider
Androski Lindsay sold 28,000 shares
President and CEO @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — ADD
1,832,704 shares ($8.8M)
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$5.09 (Nov 2025)
Current $4.25
Low $4.90
Median $4.97
High $5.41
3 analysts
$4.90
$5.41
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
| Aug 11, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 28, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
| Jan 21, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 20, 2024 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▲ +1.8% | $-0.06 — $-0.06 | -499% YoY | 1 |
| Next Q | $-0.06 ▲ +1.8% | $-0.06 — $-0.06 | 2% YoY | 1 |
| Current FY | $-0.23 ▲ +1.1% | $-0.23 — $-0.22 | 3% YoY | 2 |
| Next FY | $-0.12 | $-0.12 — $-0.12 | -112% YoY | 1 |
Latest Reports
BULLISH
8-K
7/10
Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.5M loss in Q1 2025,
May 13, 2026
BULLISH
PRESS-RELEASE
8/10
Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in licen
May 13, 2026
BULLISH
Press
9/10
Arbutus Biopharma reported improved financials for 2025 with a narrowed net loss and strong cash position, driven by cos
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $128.4M | — |
| VANGUARD GROUP INC | $44.5M | — |
| BANK OF AMERICA CORP | $8.8M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $7.5M | NEW |
| WELLS FARGO & COMPANY/MN | $803.4K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 2, 2026 | Nguyen Tuan | A | $0.00 |
| Feb 2, 2026 | Nguyen Tuan | A | $0.00 |
| Feb 2, 2026 | Androski Lindsay | A | $0.00 |
| Feb 2, 2026 | Androski Lindsay | A | $0.00 |
Reddit Sentiment
55°
Neutral
Bearish
Neutral
Bullish
6 institutional holders with $190.7M total value (39,643,759 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, BANK. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 26,702,776 | $128.4M | 67.4% | — |
| 2 | VANGUARD GROUP INC | 9,242,437 | $44.5M | 23.3% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 1,832,704 | $8.8M | 4.6% | ADD +26.3% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,562,265 | $7.5M | 3.9% | NEW |
| 5 | WELLS FARGO & COMPANY/MN | 167,021 | $803.4K | 0.4% | ADD +75.0% |
| 6 | FMR LLC | 136,556 | $656.8K | 0.3% | ADD +52.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 1,450,822 | 1,832,704 | +26.3% | $8.8M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 95,451 | 167,021 | +75.0% | $803.4K | 2025-Q4 |
| FMR LLC | ADD | 89,464 | 136,556 | +52.6% | $656.8K | 2025-Q4 |
| UBS Group AG | DOUBLED | 190,208 | 774,594 | +307.2% | $3.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 11,299 | 0 | -100.0% | $0.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 458,226 | 1,197,655 | +161.4% | $3.7M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 18,286 | 11,299 | -38.2% | $34.9K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 360,059 | 214,914 | -40.3% | $750.0K | 2025-Q1 |
| UBS Group AG | ADD | 101,005 | 192,292 | +90.4% | $671.1K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 29,486 | 18,286 | -38.0% | $63.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 697,744 | 360,059 | -48.4% | $1.2M | 2024-Q4 |
| UBS Group AG | TRIM | 168,374 | 101,005 | -40.0% | $330.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 48,831 | 70,599 | +44.6% | $230.9K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,212,246 | — | $4.7M | 2024-Q3 |
2 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | Nguyen Tuan | Chief Financial Officer | A | 73,500 | $0.00 | $0.00 |
| Feb 2, 2026 | Nguyen Tuan | Chief Financial Officer | A | 188,400 | $0.00 | $0.00 |
| Feb 2, 2026 | Androski Lindsay | President and CEO | A | 28,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Androski Lindsay | President and CEO | A | 71,700 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.3/10.
BULLISH
8-K
7/10
Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.
May 13, 2026
BULLISH
PRESS-RELEASE
8/10
Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven
May 13, 2026
BULLISH
8-K
7/10
Arbutus Biopharma announced that the FDA has granted Fast Track designation for its investigational
Apr 15, 2026
Historical analyst distribution (last covering-analyst action Nov 2025): 89% buy across 9 analysts — 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$5.09 mean target (Nov 2025)
$4.90 Low
$5.41 High
| Metric | Value |
|---|---|
| Current Price | $4.25 |
| Target Low | $4.90 |
| Target Mean | $5.09 |
| Target Median | $4.97 |
| Target High | $5.41 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.06 | $-0.06 | -499.1% | +1.8% | 0↑ 1↓ | $0.0B | -93.5% | 1 |
| Next Q 2026-09-30 |
$-0.06 | $-0.06 | $-0.06 | 1.8% | +1.8% | 0↑ 1↓ | $0.0B | 29.7% | 1 |
| Current FY 2026-12-31 |
$-0.23 | $-0.23 | $-0.22 | 2.7% | +1.1% | 1↑ 0↓ | $0.2B | 1188.1% | 2 |
| Next FY 2027-12-31 |
$-0.12 | $-0.12 | $-0.12 | -112.0% | — | 1↑ 0↓ | $0.0B | -98.5% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.055 | |
| 7d ago | $-0.056 | +0.001 |
| 30d ago | $-0.056 | +0.001 |
| 60d ago | $-0.056 | +0.001 |
| 90d ago | $-0.056 | +0.001 |
7 analyst firms have rated this stock: 6 upgrades, 2 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Aug 11, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 28, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 21, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 7, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| Sep 5, 2024 | Jefferies | MAINTAIN | Buy | Buy |
| Aug 2, 2024 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Jun 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| May 3, 2024 | Chardan Capital | REITERATE | Buy | Buy |
| Apr 4, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Mar 1, 2024 | Chardan Capital | REITERATE | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 12, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 4, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 4, 2023 | Chardan Capital | REITERATE | Buy | Buy |
| Jul 11, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 6, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Jun 22, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 22, 2023 | Chardan Capital | REITERATE | Buy | Buy |
| May 5, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Apr 28, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Apr 5, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 29, 2023 | JMP Securities | REITERATE | — | Market Outperform |
| Mar 20, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 3, 2023 | Chardan Capital | REITERATE | — | Buy |
| Mar 3, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 10, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Jun 28, 2022 | JMP Securities | MAINTAIN | — | Market Outperform |
| Mar 14, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 4, 2022 | Chardan Capital | MAINTAIN | — | Buy |
| Feb 2, 2022 | Jefferies | UPGRADE | Hold | Buy |
| Nov 8, 2021 | JMP Securities | MAINTAIN | — | Market Outperform |
| Dec 17, 2020 | HC Wainwright & Co. | INITIATE | — | Buy |
| Jul 24, 2020 | Baird | DOWNGRADE | Outperform | Neutral |
| May 19, 2020 | Wedbush | UPGRADE | Neutral | Outperform |
| Mar 27, 2020 | Baird | MAINTAIN | — | Outperform |
| Mar 6, 2020 | Chardan Capital | UPGRADE | Neutral | Buy |
| Feb 20, 2020 | Baird | INITIATE | — | Outperform |
| Feb 5, 2020 | JMP Securities | UPGRADE | Market Perform | Market Outperform |
| Jan 9, 2020 | B. Riley Securities | MAINTAIN | — | Buy |
| Oct 4, 2019 | Chardan Capital | DOWNGRADE | Buy | Neutral |
| Oct 16, 2018 | B. Riley Securities | UPGRADE | Neutral | Buy |
| Oct 15, 2018 | Wedbush | UPGRADE | Underperform | Neutral |
| Aug 13, 2018 | B. Riley Securities | MAINTAIN | Neutral | Neutral |
| Aug 13, 2018 | Wedbush | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
55°
Neutral
Bearish
Neutral
Bullish
7 mentions
1 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 4, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Mar 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 4, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 4, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 3, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
What do you think about ABUS??
▲ 1
💬 1
⚡ 0.5
What do you think about ABUS??
▲ 1
💬 1
⚡ 0.5
ABUS Settlement in Moderna Lawsuit!
▲ 1
💬 0
⚡ 0.5
ABUS Reaches Settlement with Moderna!!
▲ 1
💬 0
⚡ 0.5
Big Ruling for ABUS in Moderna Lawsuit
▲ 1
💬 1
⚡ 0.5
May 13, 2026
earnings
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><strong>Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna</
Apr 30, 2026
earnings_calendar
ABUS Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
Clinical Trial
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
Phase Phase 2 — COMPLETED
Apr 27, 2026
short_volume
Short Volume: ABUS — 62.1% short (0.4M / 0.6M)
Short: 352,835 | Exempt: 50 | TRF Vol: 568,045 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
other
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
<p align="center"><strong>Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran</strong></p>
Apr 10, 2026
short_interest
FTD: ABUS — 159,245 shares ($0.7M) failed to deliver
Settlement: 20260410, Price: $4.30, FTD Value: $684,753.5, ARBUTUS BIOPHARMA CORP COM STK
Mar 25, 2026
earnings_calendar
ABUS Q4 2025 Earnings After Market Close — 2026-03-25
Mar 24, 2026
short_volume
Short Volume: ABUS — 72.0% short (0.5M / 0.6M)
Short: 464,421 | Exempt: 0 | TRF Vol: 644,685 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
earnings
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
<p align="center"><strong>Strong financial position with cash, cash equivalents </strong><strong>and marketable securities of $91.5M as of December 20
Mar 23, 2026
short_volume
Short Volume: ABUS — 55.4% short (0.9M / 1.5M)
Short: 853,424 | Exempt: 0 | TRF Vol: 1,540,478 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Mar 3, 2026
other
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
<p>BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company
Feb 26, 2026
earnings_calendar
ABUS Q4 2025 Earnings After Market Close — 2026-02-26
Feb 18, 2026
short_interest
FTD: ABUS — 199,930 shares ($0.8M) failed to deliver
Settlement: 20260218, Price: $4.17, FTD Value: $833,708.1, ARBUTUS BIOPHARMA CORP COM STK